Due to the rapid development of bacterial resistance, there is an urgent need to explore new antibacterial agents to substitute for traditional antibiotic therapy. Photodynamic therapy has been identified as a promising bactericidal method to conquer antibiotic-resistant pathogens. To solve the problem of photosensitizer damage to normal tissues in vivo, we developed a boron-dipyrrolemethene (BODIPY)-based glycosylated photosensitizer for ablating Pseudomonas aeruginosa (P. aeruginosa). This glycosylated photosensitizer exhibited good water solubility and generated ¹O₂ rapidly in an aqueous solution under light exposure. The photosensitizer did not cause detectable toxicity to human cells in the dark. Importantly, the photosensitizer was able to selectively attach to P. aeruginosa over normal cells, thus resulting in effective pathogen ablation by reactive oxygen species. Moreover, the photosensitizer inhibited over 90% of the biofilm formation produced by P. aeruginosa. The results indicate that the design of the macromolecular photosensitizer-induced bacterial death and inhibited biofilm formation provide a novel strategy for overcoming bacterial infection.

中文翻译：

---

拟模共轭光敏剂用于铜绿假单胞菌的特异性识别和靶向光动力疗法

由于细菌抗性的迅速发展，迫切需要探索新的抗菌剂来代替传统的抗生素疗法。光动力疗法已被认为是征服抗生素抗性病原体的一种有前途的杀菌方法。为了解决光敏剂对体内正常组织的损害的问题，我们开发了一种基于硼-二吡咯二烯（BODIPY）的糖基化光敏剂，用于消融铜绿假单胞菌（P. aeruginosa）。该糖基化光敏剂表现出良好的水溶性并产生¹ O ₂在水溶液中迅速暴露于光线下。在黑暗中，光敏剂不会对人体细胞产生可检测到的毒性。重要的是，光敏剂能够选择性地附着在正常细胞上的铜绿假单胞菌上，从而导致活性氧有效地消灭病原体。此外，光敏剂抑制了由铜绿假单胞菌产生的超过90％的生物膜形成。结果表明，高分子光敏剂诱导的细菌死亡和抑制生物膜形成的设计提供了一种克服细菌感染的新策略。